(25-06-2014, 08:05 PM)bobie Wrote: Thanks lotus some things for me to digest, heres a link to the report they talk about http://press.endocrine.org/doi/full/10.1210/jc.2012-2030 which im about to read myself
Thanks bobie, I briefly looked over it, it has some sobering stats:
The aim of this study was to compare those patients who go on to request breast augmentation with those who do not and to identify markers that predict which individuals are likely to require later breast augmentation.
The breasts of transsexual natal males taking estrogen therapy follow the same stages of development as are seen in natal female puberty (2). As such, it takes 2 yr of therapy to achieve maximum growth (2). Because the bony frame of the male chest differs greatly from the female, the resulting appearance of the thorax still differs from that of similarly developed natal females, often resulting in an appearance that is deemed unsatisfactory by patients, leading approximately 60% to request an augmentation mammoplasty (3). Breast augmentation surgery in the male to female transsexual population is accordingly an issue of particular importance.
With regard to the use of antiandrogens, overall there was no statistically significant difference in the use of antiandrogens between those requiring breast augmentation and controls (see Table 3). Comparing the types of antiandrogens used, however, showed that previous spironolactone use was higher in those requesting breast augmentation as compared with other, more specific antiandrogen types (4.8 vs. 1.8%, P = 0.025) (see Table 3). There was no difference in GnRH analog use between augmentation and control groups.
I'll check out more later.